Surzebiclimab (BGB-A425): A Comprehensive Monograph on a Clinical-Stage TIM-3 Immune Checkpoint Inhibitor

Executive Summary

Surzebiclimab (BGB-A425) is an investigational, humanized immunoglobulin G1 (IgG1) variant monoclonal antibody under development by the global biotechnology company BeiGene. It is designed to function as an immune checkpoint inhibitor by targeting T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), a key negative regulator of immune responses. The mechanism of action involves binding to TIM-3 on the surface of exhausted T-cells and other immune cells, thereby blocking inhibitory signals and reactivating the body's anti-tumor immune response. This action is intended to enhance cytotoxic T-cell-mediated killing of cancer cells.

The scientific rationale for targeting TIM-3 is rooted in its frequent co-expression with other inhibitory receptors, such as PD-1 and LAG-3, on the most dysfunctional tumor-infiltrating lymphocytes. This co-expression is a hallmark of T-cell exhaustion and a primary mechanism of tumor immune evasion, particularly in patients who have developed resistance to anti-PD-1 therapies. Consequently, BeiGene's clinical development strategy for Surzebiclimab is centered on its use in combination with other checkpoint inhibitors. The program is heavily focused on evaluating Surzebiclimab alongside Tislelizumab (BGB-A317), BeiGene's anti-PD-1 antibody, and in some cases, LBL-007, an anti-LAG-3 antibody.

Currently, Surzebiclimab is advancing through clinical trials for various advanced solid tumors. The foundational Phase 1/2 trial (NCT03744468), which established the safety and recommended dose for combination therapy, is now complete. The program has progressed to a randomized Phase 2 study (NCT05909904) investigating a triple-combination regimen as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Other indications of interest include non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

The development of Surzebiclimab occurs within a challenging competitive landscape. The TIM-3 target class has seen numerous high-profile clinical failures and program discontinuations from major pharmaceutical companies, including Novartis, GSK, and Bristol Myers Squibb. This history underscores the significant clinical and biological hurdles associated with targeting this pathway. As one of the few remaining late-stage TIM-3 inhibitors being advanced by a major biopharmaceutical company, Surzebiclimab represents a high-risk, high-reward asset. Its success could validate TIM-3 as a crucial therapeutic target and establish a new paradigm in combination immunotherapy. Conversely, its failure would add to a growing body of evidence suggesting the target is more complex than initially anticipated. The outcomes of its ongoing clinical trials are therefore of significant interest to the field of immuno-oncology and will be a critical determinant of the future of TIM-3-targeted therapies.

I. Drug Profile and Molecular Characteristics

This section provides a comprehensive overview of Surzebiclimab's fundamental identity, including its nomenclature, structural properties, and manufacturing details. This information serves as a foundational reference for the molecule.

1.1. Identification and Nomenclature

Surzebiclimab is identified by a range of names and codes across various chemical, regulatory, and drug databases, which is typical for an investigational therapeutic. Its International Nonproprietary Name (INN) is Surzebiclimab.[1] The primary development code used by its sponsor, BeiGene, is BGB-A425, which is frequently used in scientific literature and clinical trial registries.[2]

For precise identification and cross-referencing, the following registry numbers have been assigned:

• DrugBank Accession Number: DB16669 [2]
• CAS Registry Number: 2342597-90-2 [5]
• Unique Ingredient Identifier (UNII): 53YMC3A1CU [5]
• United States Adopted Name (USAN) File Number: KL-130 [6]
• World Health Organization (WHO) Number: 11453 [6]

Synonyms used to describe the molecule include "Anti-TIM-3 monoclonal antibody BGB-A425" and "Humanised IgG1-variant monoclonal antibody against TIM-3".[2]

1.2. Structural and Physicochemical Properties

Surzebiclimab is classified as a biotech therapeutic, specifically a protein-based therapy modality.[2] Its molecular structure is that of a humanized immunoglobulin G1 (IgG1) kappa monoclonal antibody.[1] The "humanized" designation indicates that the antibody was originally raised in a non-human species (e.g., mouse) and subsequently engineered to replace most of its protein sequences with human equivalents, leaving only the antigen-binding loops (complementarity-determining regions) of non-human origin. This process is crucial for reducing the risk of immunogenicity when administered to patients.

The molecule is further described as an "IgG1-variant".[8] While a standard human IgG1 isotype possesses potent effector functions, such as the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), this can be therapeutically undesirable when the target is expressed on beneficial immune cells. In the case of Surzebiclimab, the target (TIM-3) is present on effector T-cells that the therapy aims to activate. A standard IgG1 could inadvertently mark these T-cells for destruction by other immune cells, such as natural killer (NK) cells, thereby counteracting its intended immunomodulatory effect. The "variant" designation strongly implies that the Fc region of the antibody has been engineered with specific mutations (e.g., LALA mutations) to reduce or abrogate its binding to Fc-gamma receptors (FcγR), thus minimizing effector functions and preventing the depletion of the target T-cell population. This sophisticated protein engineering approach is consistent with strategies used for other modern immunomodulatory antibodies, including BeiGene's anti-PD-1 agent Tislelizumab, which was also designed to minimize FcγR binding.[11]

The approximate molecular weight of Surzebiclimab is 145.72 kDa.[8] For research and clinical use, it is typically supplied as a liquid formulation, appearing as a colorless to light-yellow solution.[8] The formulation buffer is often a 0.01 M phosphate-buffered saline (PBS) solution at a physiological pH of 7.4.[1] Research-grade batches of the antibody demonstrate high purity, typically exceeding 95% as determined by SDS-PAGE analysis.[1]

1.3. Manufacturing and Production

As a recombinant monoclonal antibody, Surzebiclimab is produced using mammalian cell culture technology. The specific expression system is Chinese hamster ovary (CHO) cells, a well-established and robust platform for the large-scale, good manufacturing practice (GMP) compliant production of therapeutic proteins.[12] One source also specifies the use of the XtenCHO cell line.[1] Following expression, the antibody is purified from the cell culture supernatant using standard chromatography techniques, such as Protein A/G affinity chromatography.[1]

The primary developer and sponsor of Surzebiclimab's clinical program is BeiGene, Ltd., a global oncology company.[6] Manufacturing activities are associated with facilities such as BeiGene Guangzhou Biologics Manufacturing Co. Ltd..[4] Some records also credit BeOne Medicines Ltd. with initial development.[4]

Table 1: Key Identifiers and Properties of Surzebiclimab
Generic Name (INN)	Surzebiclimab
Developer Code(s)	BGB-A425, BGBA-425
Drug Type	Biotech, Monoclonal Antibody
DrugBank ID	DB16669
CAS Number	2342597-90-2
UNII	53YMC3A1CU
WHO Number	11453
Class	Antineoplastics, Immunotherapies
Isotype	Humanized IgG1 kappa (variant)
Molecular Weight	~145.72 kDa
Developer/Sponsor	BeiGene, Ltd.

II. Mechanism of Action and Pharmacological Rationale

This section deconstructs the biological basis for Surzebiclimab's anti-tumor activity, detailing the TIM-3 immune checkpoint pathway, the molecule's specific mode of action, and the compelling scientific rationale for its use in combination with other immunotherapies.

2.1. The TIM-3 Immune Checkpoint Pathway in Oncology

T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) is a transmembrane protein that functions as a critical inhibitory immune checkpoint receptor.[3] It is also known by the designations HAVCR2 (Hepatitis A virus cellular receptor 2) and CD366.[1] TIM-3 is expressed on a variety of immune cells, including T-cells, regulatory T-cells (Tregs), NK cells, and myeloid cells such as dendritic cells and macrophages.[14]

In the context of oncology, the expression of TIM-3 on T-cells is of paramount importance. It is a key marker of T-cell exhaustion, a state of cellular dysfunction that arises after chronic antigen exposure, such as that occurring within a tumor microenvironment.[14] Tumor-infiltrating lymphocytes (TILs) that express high levels of TIM-3 are typically characterized by poor proliferative capacity and an inability to produce effector cytokines like interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α).[3]

The inhibitory function of TIM-3 is triggered upon binding to its natural ligands. Key ligands include galectin-9 and phosphatidylserine (PtdSer), the latter of which is exposed on the surface of apoptotic cells.[3] When these ligands engage TIM-3 on a T-cell, an intracellular signaling cascade is initiated that actively suppresses T-cell activation and effector functions. By exploiting this pathway, tumors can effectively "switch off" the T-cells that would otherwise recognize and eliminate malignant cells, thereby facilitating tumor-mediated immune suppression and escape.[3]

2.2. Molecular Engagement and Action of Surzebiclimab

Surzebiclimab is designed as a potent and specific inhibitor of the TIM-3 signaling pathway.[4] It functions as a competitive antagonist by binding with high affinity to the extracellular domain of human TIM-3.[8] Preclinical measurements have determined its dissociation constant ($K_D$) to be approximately 0.36 nM, indicating a very strong binding interaction.[8]

By physically occupying the ligand-binding site on the TIM-3 receptor, Surzebiclimab prevents the engagement of TIM-3 by its natural ligands, PtdSer and galectin-9.[3] This blockade effectively interrupts the downstream inhibitory signaling cascade, thereby "releasing the brakes" on the suppressed immune cell.

2.3. Immunomodulatory Effects and Anti-Neoplastic Activity

The primary pharmacological consequence of Surzebiclimab's action is the abrogation of T-cell inhibition.[3] This leads to a cascade of desired immunomodulatory effects:

1. Reactivation of T-cells: By blocking the inhibitory signal, Surzebiclimab restores the function of previously exhausted, antigen-specific T-lymphocytes.[3]
2. Enhanced Cytotoxicity: The reactivated T-cells regain their ability to mount a cytotoxic response, leading to enhanced T-cell-mediated lysis of tumor cells and a consequent reduction in tumor cell proliferation.[3]
3. Broadened Immune Response: The effects of Surzebiclimab are not limited to T-cells. Preclinical studies have shown that it can also enhance the natural killer (NK) cell-mediated cytotoxicity against tumor cells, suggesting a wider impact on the innate anti-tumor immune response.[8]
4. T-lymphocyte Stimulation: The overall effect can be summarized as a potent stimulation of T-lymphocytes and other anti-tumor immune effectors.[18]

2.4. Rationale for Combination Therapy

The clinical development strategy for Surzebiclimab is almost exclusively focused on combination therapy, a decision driven by a strong biological rationale. Tumor immune escape is a complex process that rarely relies on a single pathway. Tumors frequently upregulate multiple distinct immune checkpoint receptors to ensure robust suppression of the immune system.

A critical observation is that TIM-3, PD-1, and another checkpoint, LAG-3, are often co-expressed on the same TILs, particularly those exhibiting the most severe exhaustion phenotype.[16] This suggests that these pathways cooperate to enforce and maintain T-cell dysfunction.[11]

Furthermore, resistance to anti-PD-1 monotherapy, a cornerstone of modern immuno-oncology, is a major clinical challenge. A significant body of evidence indicates that this resistance is often mediated by the compensatory upregulation of other checkpoint pathways, including TIM-3 and LAG-3.[19] Preclinical studies have demonstrated that treatment with an anti-PD-1 antibody can actively increase the expression of TIM-3 and LAG-3 on T-cells, representing a mechanism of adaptive resistance.[20] This creates a direct causal link: while anti-PD-1 therapy can be effective, the tumor microenvironment can adapt by strengthening alternative inhibitory pathways to re-establish immune suppression.

This understanding transforms the rationale for combination therapy from a simple "more is better" approach into a sophisticated, mechanistically driven strategy. By simultaneously blocking PD-1 with an agent like Tislelizumab and TIM-3 with Surzebiclimab, the goal is to prevent this adaptive resistance from occurring. This dual blockade could potentially overcome both pre-existing and treatment-induced resistance, leading to deeper, more durable anti-tumor responses than could be achieved with either agent alone.[11]

III. Preclinical and Pharmacodynamic Profile

This section details the non-clinical evidence from in vitro and in vivo studies that substantiates Surzebiclimab's mechanism of action and provides the scientific foundation for its clinical development.

3.1. In Vitro Activity

A series of in vitro experiments have been conducted to characterize the molecular and cellular effects of Surzebiclimab. These studies confirm its ability to bind its target and elicit a functional immune response:

• Ligand Blockade: Functional assays using Surzebiclimab at concentrations ranging from 0.1 to 100 µg/mL demonstrated that it efficiently blocks the molecular interaction between the TIM-3 receptor and its ligand, phosphatidylserine (PtdSer).[8]
• T-Cell Activation: This blockade of inhibitory signaling translates directly into the activation of key immune cells. Surzebiclimab was shown to significantly enhance the production of interferon-gamma (IFN-γ) from primary T-cells.[8] IFN-γ is a pleiotropic cytokine that is critical for orchestrating an effective anti-tumor immune response.
• Broadened Immune Stimulation: The immunomodulatory effects extend beyond T-cells. Surzebiclimab was also found to augment T-cell responses to allogeneic antigens and to boost the cytotoxic activity of natural killer (NK) cells against tumor cell lines.[8]
• Receptor Internalization: An additional mechanism observed in vitro is that Surzebiclimab can induce the internalization of the TIM-3 receptor from the cell surface.[8] By removing the receptor, the drug may provide a more sustained blockade of the inhibitory pathway, even after the antibody has dissociated.

3.2. In Vivo Animal Models

The promising in vitro results were further validated in in vivo animal models of cancer, which provided the crucial proof-of-concept for combination therapy:

• Xenograft Model: In a mouse xenograft cancer model, the combination of Surzebiclimab (BGB-A425) with the anti-PD-1 antibody Tislelizumab (BGB-A317) resulted in significant inhibition of tumor growth.[8]
• Syngeneic Models and Combination Synergy: More advanced translational studies in syngeneic mouse models (which have a competent immune system) further solidified the rationale for combination therapy. These experiments confirmed that a dual blockade of the PD-1 and TIM-3 pathways led to significantly enhanced tumor growth inhibition compared to anti-PD-1 monotherapy.[20]
• Triple Blockade Rationale: Critically, these models were also used to test a triple-blockade strategy (PD-1/LAG-3/TIM-3). The results demonstrated that the triple combination produced even greater anti-tumor activity than either dual combination, evidenced by trends of increased tumor growth inhibition and a higher rate of complete tumor eradication (tumor-free incidence).[20]

This preclinical data provides a clear and compelling justification for BeiGene's clinical strategy. The evidence strongly suggests that the full therapeutic potential of Surzebiclimab is unlocked when it is used not as a standalone agent, but as a synergistic partner to overcome the limitations of existing immunotherapies. This positions Surzebiclimab as a "backbone-enhancer" rather than a new backbone therapy itself, a strategic decision that has profound implications for its clinical development pathway and eventual commercial positioning. Its success is therefore intrinsically linked to its ability to prove that the combination is superior to the established standard of care.

3.3. Pharmacodynamics (PD) in Clinical Trials

While specific pharmacodynamic data from patients treated with Surzebiclimab has not yet been published, the assessment of its biological effects in humans is a core component of the clinical trial designs. Both the completed Phase 1/2 study (NCT03744468) and ongoing trials include pharmacodynamic evaluations as key objectives.[11]

These assessments are designed to confirm that the drug is engaging its target and producing the intended immunological changes in patients. This typically involves collecting serial blood and tumor biopsy samples to analyze:

• Changes in the frequency and activation status of peripheral and tumor-infiltrating immune cell populations (e.g., CD8+ T-cells, NK cells).
• Modulation of cytokine levels in the blood (e.g., an increase in IFN-γ).
• Changes in the expression of TIM-3 and other checkpoint markers on T-cells before and after treatment.

This data will be crucial for establishing a clear link between drug exposure, target engagement, biological response, and ultimately, clinical efficacy.

IV. Clinical Development Program

The clinical development of Surzebiclimab is a focused and strategically designed program aimed at evaluating its safety and efficacy, primarily as part of combination immunotherapy regimens for advanced cancers. This section provides a detailed analysis of the key clinical trials that constitute this program.

4.1. Overview of Clinical Strategy and Status

Surzebiclimab is under active clinical development by BeiGene for the treatment of advanced malignancies and various solid tumors.[13] Its development status is multifaceted. While some industry databases report its highest development phase as Phase 3, this largely refers to its inclusion in a long-term extension study (NCT04164199) that allows continued treatment for patients from earlier trials.[4] The most advanced, indication-seeking trials that are actively evaluating the drug in new patient populations are currently in Phase 2.[21] The foundational Phase 1/2 dose-finding and initial efficacy study (NCT03744468) has been completed.[4]

4.2. In-Depth Analysis of Key Clinical Trials

4.2.1. NCT03744468: The Foundational Phase 1/2 Study

• Title: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors.[27]
• Status: Completed. The study's completion date was February 6, 2025.[4]
• Design: This was a pivotal open-label, multicenter, non-randomized trial that served as the entry point for Surzebiclimab into clinical testing.
• Phase 1 (Dose Escalation): This portion followed a standard 3+3 design to evaluate the safety and tolerability of increasing doses of Surzebiclimab administered in combination with a fixed dose of Tislelizumab. The primary objective was to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) for the combination.[11]
• Phase 2 (Dose Expansion): Once the RP2D was established, the study enrolled patients into expansion cohorts to gather preliminary data on the safety and efficacy of both a doublet combination (Surzebiclimab + Tislelizumab) and a triplet combination (Surzebiclimab + Tislelizumab + LBL-007, an anti-LAG-3 antibody) in specific tumor types.[19]
• Patient Population: The trial enrolled patients with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors who had either failed standard systemic therapy or for whom no standard treatment was available.[19] The dose-expansion cohorts specifically focused on patients with Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), and Renal Cell Carcinoma (RCC).[14]
• Results: As the trial only recently concluded, the final, comprehensive results have not yet been made public through peer-reviewed publication or major conference presentation. The data is presumably under analysis and will be critical for informing the future direction of the Surzebiclimab program.

4.2.2. NCT05909904: The Randomized Phase 2 HNSCC Study

• Title: A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.[4]
• Status: Active, not recruiting.[4]
• Design: This is a crucial ongoing study that directly tests the hypotheses generated from preclinical data. It is a randomized, multi-arm trial designed to evaluate the efficacy of various Tislelizumab-based combinations. A key arm of this study is investigating the triplet regimen of Tislelizumab + Surzebiclimab + LBL-007.[20]
• Patient Population: The study is focused on the first-line treatment setting for patients with recurrent or metastatic HNSCC whose tumors express PD-L1 (Combined Positive Score ≥ 1).[20]
• Rationale and Significance: This trial represents a direct clinical test of the preclinical finding that a triple blockade of PD-1, TIM-3, and LAG-3 may offer superior anti-tumor activity, particularly in tumor types like HNSCC, which in silico analyses predicted would be highly responsive.[20] A positive outcome from this trial would provide strong validation for this therapeutic strategy.
• Results: The trial is ongoing, with an estimated study completion date in May 2026.[26] No efficacy or safety data are available at this time.

4.2.3. NCT04164199: The Phase 3 Long-Term Extension Study

• Title: An Open-Label, Multicenter, Long-Term Extension Study of Treatment With Tislelizumab, Pamiparib, and Other Investigational Agents in Patients With Advanced Malignancies.[4]
• Status: Enrolling by invitation only.[29]
• Design: This is a "basket" or "platform" extension study. Its purpose is not to test a new hypothesis in a new patient population, but rather to allow patients who were enrolled in and benefiting from treatment in a prior BeiGene-sponsored "parent study" to continue receiving their investigational therapy.[30] The study includes multiple arms for various BeiGene investigational agents. Arm M is specifically designated for patients continuing on the Tislelizumab + Surzebiclimab combination therapy.[29]
• Significance: While designated as Phase 3, this study is not a pivotal registration trial for a new indication. Its primary value is in gathering crucial long-term safety, efficacy, and survival data for patients who have demonstrated a durable benefit from the combination therapy.

4.3. Investigational Indications

The clinical development program for Surzebiclimab is broadly focused on advanced solid tumors.[2] Within this broad category, specific cancer types have been prioritized for investigation in dedicated trial cohorts based on scientific rationale and unmet medical need:

• Head and Neck Squamous Cell Carcinoma (HNSCC): This is a primary focus, with dedicated cohorts in NCT03744468 and the ongoing randomized Phase 2 trial, NCT05909904.[13]
• Non-Small Cell Lung Cancer (NSCLC): A key indication for many immunotherapies, NSCLC was included in the expansion phase of NCT03744468.[4]
• Renal Cell Carcinoma (RCC): This immunologically responsive tumor type was also an indication of interest in the NCT03744468 expansion cohorts.[13]

Table 2: Summary of Key Surzebiclimab Clinical Trials
NCT ID	Phase	Status	Primary Indication(s)	Key Intervention Arm(s) with Surzebiclimab	Primary Objective(s)
NCT03744468	Phase 1/2	Completed	Advanced Solid Tumors (HNSCC, NSCLC, RCC expansion)	Surzebiclimab + Tislelizumab; Surzebiclimab + Tislelizumab + LBL-007	Safety, Tolerability, RP2D, Preliminary Antitumor Activity
NCT05909904	Phase 2	Active, Not Recruiting	First-Line Recurrent/Metastatic HNSCC (PD-L1+)	Surzebiclimab + Tislelizumab + LBL-007	Overall Response Rate (ORR), Progression-Free Survival (PFS)
NCT04164199	Phase 3 (Extension)	Enrolling by Invitation	Advanced Malignancies (Long-term follow-up)	Surzebiclimab + Tislelizumab	Long-term Safety and Efficacy

V. Pharmacokinetic (PK) Profile

This section outlines the planned pharmacokinetic evaluation of Surzebiclimab and provides a prospective analysis of its likely PK profile based on its molecular class and data from analogous therapeutic antibodies, as specific clinical PK data for Surzebiclimab has not yet been publicly disclosed.

5.1. Clinical Pharmacokinetic Evaluation

The characterization of Surzebiclimab's pharmacokinetic profile is a key secondary objective within its clinical development program, particularly in the foundational NCT03744468 trial.[11] The study was explicitly designed to collect data to define how the drug is absorbed, distributed, metabolized, and eliminated (ADME) in patients with advanced solid tumors.

The trial protocol specifies the measurement of standard pharmacokinetic parameters for intravenously administered monoclonal antibodies, including [19]:

• Maximum Concentration ($C_{max}$): The peak plasma concentration of the drug after infusion.
• Minimum Concentration ($C_{min}$): The trough concentration of the drug just before the next dose, which is important for assessing steady-state exposure.
• Area Under the Curve (AUC): A measure of the total drug exposure over a given time interval (e.g., 0 to 21 days).
• Clearance (CL): The rate at which the drug is removed from the body.
• Volume of Distribution ($V_z$): The theoretical volume into which the drug distributes in the body.
• Terminal half-life ($t_{1/2}$): The time it takes for the plasma concentration of the drug to decrease by half during the elimination phase.

A critical component of the PK assessment is the evaluation of immunogenicity. The trial protocol includes an endpoint to measure the percentage of participants who develop anti-drug antibodies (ADAs) against Surzebiclimab (BGB-A425).[19] As a "humanized" antibody, Surzebiclimab contains non-human protein sequences in its antigen-binding regions. These sequences, though small, can be recognized as foreign by the patient's immune system, triggering the production of ADAs. The formation of ADAs can have significant clinical consequences, including accelerated drug clearance (reducing efficacy), neutralization of the drug's activity, or, in some cases, induction of hypersensitivity reactions. Therefore, a low rate of ADA formation is a crucial prerequisite for the drug's continued development and eventual success. The immunogenicity data from NCT03744468 will serve as a vital indicator of the success of the antibody's humanization process.

5.2. Expected Profile and Analogues

While awaiting specific data for Surzebiclimab, its likely pharmacokinetic profile can be inferred from its nature as a humanized IgG1 monoclonal antibody and by examining data from other therapeutic antibodies used in oncology.

For instance, serplulimab, a humanized IgG4 anti-PD-1 antibody, exhibits characteristics typical of this class: a long elimination half-life of approximately 24.3 days at steady-state, a relatively small volume of distribution (around 5.73 L), and clearance that is influenced by target-mediated drug disposition (TMDD), where binding to the target receptor contributes to the drug's elimination.[32]

Surzebiclimab, as an IgG1 antibody, is expected to display a similarly long terminal half-life, likely spanning multiple days to weeks. This pharmacokinetic property is what enables the convenient intermittent dosing schedules used in its clinical trials, such as every 21 days.[11] Its clearance will likely occur through non-specific catabolism into peptides and amino acids, a common fate for therapeutic proteins, as well as through TMDD via its binding to the TIM-3 receptor.[32]

Following the analysis of clinical data, population pharmacokinetic (PopPK) models will likely be developed. These models, similar to those used for serplulimab, will help to identify patient-specific covariates (such as body weight, gender, baseline albumin levels, or tumor burden) that may influence drug exposure.[33] However, for many monoclonal antibodies, the impact of these covariates is often not clinically significant enough to necessitate dose adjustments for different patient subgroups.

VI. Safety and Tolerability Profile

As Surzebiclimab is an investigational agent, its definitive safety profile in humans is still being established through ongoing clinical trials. However, based on its mechanism of action as an immune checkpoint inhibitor and the known safety profiles of analogous drugs, a prospective safety profile can be constructed. This section outlines the anticipated adverse events and the safety monitoring strategies employed in its clinical development.

6.1. Anticipated Class-Related Adverse Events

Surzebiclimab's primary function is to reactivate the immune system. While this is the basis of its anti-tumor effect, it also carries the inherent risk of inducing an overactive immune response that can lead to inflammation and damage in healthy tissues. These on-target, off-tumor toxicities are known as immune-related adverse events (irAEs) and are a hallmark of all immune checkpoint inhibitors.

Based on the safety profiles of approved checkpoint inhibitors targeting pathways like PD-1 (e.g., cemiplimab), the following types of irAEs are anticipated with Surzebiclimab, particularly when used in combination with other checkpoint inhibitors [35]:

• Dermatologic: Rash, pruritus (itching), and more severe reactions like Stevens-Johnson syndrome are possible.[35]
• Gastrointestinal: Colitis (inflammation of the colon), presenting as diarrhea, abdominal pain, and bloody stools, is a common irAE.[35]
• Hepatic: Immune-mediated hepatitis, characterized by elevated liver enzymes (AST, ALT) and bilirubin, can occur.[35]
• Pulmonary: Pneumonitis (inflammation of the lungs), which can manifest as cough, shortness of breath, and chest tightness, is a serious but less common irAE.[35]
• Endocrine: Endocrinopathies are frequent and can affect the thyroid (hypothyroidism, hyperthyroidism), pituitary gland (hypophysitis), adrenal glands (adrenal insufficiency), and pancreas (type 1 diabetes).[35]
• Renal: Immune-mediated nephritis with renal dysfunction can occur, monitored by changes in creatinine.[35]
• Neurologic and Musculoskeletal: Less common but potentially severe irAEs include myositis, myocarditis, meningitis, and neuropathies.[35]

In addition to irAEs, infusion-related reactions are a potential risk with any intravenously administered monoclonal antibody. These can range from mild (fever, chills, flushing) to severe (anaphylaxis) and typically occur during or shortly after the infusion.[35]

A central challenge for the Surzebiclimab program is the management of cumulative toxicity. The therapeutic strategy relies on combining multiple checkpoint inhibitors (anti-TIM-3, anti-PD-1, and anti-LAG-3). Each of these agents carries its own risk of inducing irAEs. Blocking multiple, non-redundant inhibitory pathways simultaneously is expected to produce a more profound state of immune activation. While this is the goal for achieving a greater anti-tumor effect, it logically follows that it will also amplify the risk of off-target immune attacks on healthy organs. This could lead to an increase in both the frequency and the severity of irAEs compared to monotherapy. Therefore, a key determinant of the combination's clinical viability will be its therapeutic index—whether the gains in efficacy are sufficient to justify the potential increase in toxicity. A high rate of severe (Grade 3-4) irAEs could limit the combination's use to only the fittest patients or render it too toxic for broad clinical application, representing a major risk for the entire development program.

6.2. Safety Monitoring in Clinical Trials

Given these potential risks, the rigorous monitoring of safety and tolerability is a primary objective of all Surzebiclimab clinical trials. The Phase 1 portion of the NCT03744468 study was specifically designed to establish the safety profile and determine a dose that is both biologically active and acceptably safe for further study.[11]

Safety monitoring protocols in these trials are comprehensive and include [19]:

• Systematic recording and grading of all adverse events (AEs) and serious adverse events (SAEs) according to standardized criteria (e.g., CTCAE).
• Close monitoring for pre-defined adverse events of special interest, particularly the spectrum of potential irAEs.
• Regular clinical assessments, including physical examinations and vital signs.
• Frequent laboratory testing to monitor hematologic, hepatic, renal, and endocrine function.
• Periodic electrocardiograms (ECGs) to monitor for cardiac toxicity.

This intensive monitoring allows for the early detection and management of adverse events, which is critical for ensuring patient safety in immuno-oncology trials.

VII. Competitive Landscape and Strategic Analysis

This section analyzes Surzebiclimab's position within the broader pharmaceutical industry, focusing on the uniquely challenging development landscape for TIM-3 inhibitors and its strategic importance to BeiGene's immuno-oncology franchise.

7.1. The TIM-3 Inhibitor Field: A High-Failure Target

The pursuit of TIM-3 as a therapeutic target in oncology has been characterized by significant setbacks and a high rate of clinical failure. Despite strong preclinical rationale, translating this into clinical benefit has proven to be exceptionally difficult. Numerous major pharmaceutical companies have invested heavily in developing anti-TIM-3 monoclonal antibodies, only to discontinue their programs after disappointing results in mid- to late-stage trials.

This "graveyard" of failed TIM-3 assets underscores the inherent risks in this target class. Notable discontinuations include [38]:

• Sabatolimab (MBG453): Developed by Novartis, this was one of the most advanced TIM-3 inhibitors. However, its development was halted in January 2024 after Phase 3 trials in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) failed to meet their primary endpoints.[38]
• Cobolimab (TSR-022): GSK's anti-TIM-3 antibody was being evaluated in combination with an anti-PD-1 agent in NSCLC. The program was terminated in 2025 after a Phase 3 study (COSTAR Lung) failed.[38]
• Lomvastomig (RG7769): A bispecific antibody from Roche targeting both TIM-3 and PD-1, discontinued in Phase 2 in 2022.[38]
• BMS-986258: Bristol Myers Squibb, a leader in immuno-oncology, terminated a Phase 1/2 trial of its anti-TIM-3 antibody in combination with nivolumab in January 2025.[38]
• Other Discontinued Programs: Assets from several other companies, including Lilly (LY3321367), Incyte (Verzistobart), and AstraZeneca (Sabestomig), have also been discontinued in early-stage development.[38]

Table 3: Competitive Landscape of Selected Clinical-Stage TIM-3 Inhibitors
Project Name	Company/Developer	Mechanism	Highest Phase Reached	Current Status (as of latest data)
Surzebiclimab	BeiGene	Anti-TIM-3 mAb	Phase 2/3	Active
Cobolimab	GSK	Anti-TIM-3 mAb	Phase 3	Terminated
Sabatolimab	Novartis	Anti-TIM-3 mAb	Phase 3	Discontinued
Lomvastomig	Roche	Anti-TIM-3/PD-1 Bispecific	Phase 2	Discontinued
BMS-986258	Bristol Myers Squibb	Anti-TIM-3 mAb	Phase 1/2	Terminated
Verzistobart	Incyte	Anti-TIM-3 mAb	Phase 1	Discontinued

7.2. Surzebiclimab's Strategic Position

The extensive list of failures from well-resourced competitors dramatically shapes the strategic context for Surzebiclimab. It is now positioned as one of the very few remaining anti-TIM-3 monoclonal antibodies still in active, late-stage clinical development at a major biopharmaceutical company.[38]

This creates a high-risk, high-reward scenario for BeiGene. The repeated failures by others could suggest a fundamental flaw in the TIM-3 therapeutic hypothesis or unforeseen biological complexities that make the target intractable. However, if Surzebiclimab succeeds where others have failed—perhaps due to a superior molecular design, a more effective combination strategy, or selection of the right patient populations—BeiGene could potentially capture an entire therapeutic class with very limited near-term competition. Its ongoing clinical trials are therefore not just testing a single drug, but are, in many ways, a pivotal test for the viability of the entire TIM-3 inhibitor class.

7.3. BeiGene's Immuno-Oncology Strategy

Surzebiclimab is not a standalone project; it is a critical component of BeiGene's broader, multi-asset strategy in immuno-oncology. This strategy is anchored by the company's internally developed anti-PD-1 antibody, Tislelizumab (marketed as Tevimbra®).[13]

BeiGene's approach is to build a portfolio of novel immunomodulatory agents—such as Surzebiclimab (anti-TIM-3), Ociperlimab (anti-TIGIT), and others—that can be combined with its Tislelizumab backbone.[4] This strategy offers several significant advantages:

1. Creation of Proprietary Regimens: By owning both the foundational "backbone" therapy (Tislelizumab) and the novel "add-on" agents (Surzebiclimab), BeiGene can develop and commercialize proprietary, high-value combination therapies.
2. Control Over Development: This ownership model gives the company complete control over the design and execution of combination clinical trials, avoiding the complexities and economic compromises of partnering with another company for their checkpoint inhibitor.
3. Lifecycle Management: Developing novel combinations provides a path to expand the use of Tislelizumab into new indications and lines of therapy, effectively managing its product lifecycle and defending its market position.

In this context, Surzebiclimab serves as a key "shot on goal" to create a next-generation immunotherapy regimen that could potentially be superior to anti-PD-1 monotherapy or other existing standards of care.

VIII. Regulatory Status and Development Outlook

This section provides a summary of Surzebiclimab's current regulatory standing across major global agencies and offers a prospective analysis of its potential pathway toward market approval.

8.1. Current Global Regulatory Status

Surzebiclimab is an investigational drug candidate and, as of the latest available information, has not received marketing approval from any regulatory agency in the world.[24] Its use is restricted to clinical trials.

A review of regulatory databases and company disclosures indicates that no marketing applications, such as a Biologics License Application (BLA) in the United States or a Marketing Authorisation Application (MAA) in the European Union, have been submitted for Surzebiclimab to the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).[40] Similarly, there is no evidence of a submission to the Australian Therapeutic Goods Administration (TGA).[40] The numerous regulatory updates and approvals associated with its developer, BeiGene, pertain to its other approved products, primarily the BTK inhibitor Brukinsa® (zanubrutinib) and the anti-PD-1 antibody Tevimbra® (tislelizumab).[24]

8.2. Future Projections and Pathway to Approval

The future development and potential regulatory approval of Surzebiclimab are entirely contingent on the outcomes of its ongoing and planned clinical trials. The pathway to market will likely follow these key steps:

1. Data Readout from Phase 2: The first critical milestone will be the data readout from the completed Phase 1/2 study (NCT03744468) and, more importantly, the randomized Phase 2 study in HNSCC (NCT05909904). These trials must demonstrate not only that the Surzebiclimab-containing combinations are safe and active, but also that they provide a clinically meaningful benefit that is substantial enough to warrant further development.
2. Pivotal Phase 3 Trial: Assuming the Phase 2 data are positive, BeiGene will need to design and conduct at least one large, well-controlled, pivotal Phase 3 registration study. This trial would likely compare a Surzebiclimab-based combination regimen against the current standard of care in a specific, well-defined patient population (e.g., first-line R/M HNSCC).
3. Regulatory Submissions: If the Phase 3 trial successfully meets its primary endpoint(s) (e.g., a statistically significant improvement in Progression-Free Survival or Overall Survival), BeiGene would then compile the complete data package for submission to regulatory authorities like the FDA and EMA.

Given the high unmet medical need in cancer patients who are resistant to or have failed existing immunotherapies, a strong positive result in a key trial could make Surzebiclimab eligible for expedited regulatory programs, such as the FDA's Breakthrough Therapy Designation or Priority Review, which are designed to accelerate the development and review of promising new medicines.[46] However, no such designations have been granted to Surzebiclimab to date.

The extensive experience BeiGene has gained in successfully navigating the complex regulatory landscapes of the United States, Europe, and other global regions with its other oncology products provides a significant advantage. The company has established the internal capabilities, expertise, and relationships with regulatory agencies necessary to manage the submission and review process for a complex biologic like Surzebiclimab.[24] This institutional experience effectively de-risks the regulatory execution phase of the program, allowing the company to focus on the primary challenge: generating positive clinical data.

IX. Concluding Analysis and Recommendations

This final section synthesizes the comprehensive data on Surzebiclimab to provide a holistic assessment of its therapeutic potential, the significant risks and challenges facing its development, and a forward-looking perspective on its future.

9.1. Synthesis of Findings and Overall Potential

Surzebiclimab embodies a scientifically robust and mechanistically rational approach to addressing a critical challenge in modern oncology: resistance to immune checkpoint inhibitors. Its design as a high-affinity antagonist of the TIM-3 pathway is supported by compelling preclinical data that validates its ability to reactivate exhausted immune cells and demonstrates clear synergy when combined with inhibitors of the PD-1 and LAG-3 pathways. The clinical development program, strategically centered on these combination therapies, directly reflects this strong scientific foundation.

The drug's potential is significant. If successful, it could validate TIM-3 as a major druggable target in immuno-oncology, a goal that has eluded many of the world's largest pharmaceutical companies. For patients, it could offer a new therapeutic option capable of overcoming resistance and improving outcomes in difficult-to-treat cancers like HNSCC and NSCLC. For its developer, BeiGene, it represents a key asset in its strategy to build a leading, multi-faceted immuno-oncology portfolio, with the potential to establish a proprietary, first-in-class combination regimen.

However, this potential is counterbalanced by the considerable risks inherent in its development. The success of Surzebiclimab is not merely a test of one molecule but a pivotal trial for the broader therapeutic hypothesis of multi-checkpoint blockade and the specific viability of targeting TIM-3.

9.2. Key Risks and Challenges

The Surzebiclimab program faces three primary hurdles that will determine its ultimate fate:

1. Clinical Efficacy: The most significant risk is that the addition of Surzebiclimab to a PD-1 inhibitor backbone will fail to produce a sufficient magnitude of clinical benefit to be meaningful for patients and justify regulatory approval. The history of the TIM-3 field is a stark reminder that promising preclinical data does not always translate into clinical success. The failure of numerous other TIM-3 inhibitors suggests that the biological redundancy or complexity of the immune system may be greater than anticipated, and simply blocking this one additional pathway may not be enough to overcome resistance in a broad patient population.
2. Cumulative Toxicity: The strategy of combining multiple checkpoint inhibitors carries the inherent risk of creating an unmanageable toxicity profile. The potential for an amplified frequency and severity of immune-related adverse events resulting from dual or triple blockade could severely limit the therapeutic window of the regimen. A combination that is too toxic for the average patient, even if effective, will have limited clinical utility.
3. Biomarker Development: A major challenge for the field of immuno-oncology is the identification of predictive biomarkers to select patients who are most likely to respond to a given therapy. The preclinical work on Surzebiclimab hinted at using gene signatures to predict responsiveness.[20] A failure to validate such a biomarker in clinical trials could hinder the design of successful pivotal studies and limit the drug's commercial potential by making it difficult to identify the optimal patient population.

9.3. Future Directions and Final Outlook

The immediate trajectory of the Surzebiclimab program will be dictated by the data from its ongoing clinical trials. The final results from the completed Phase 1/2 study (NCT03744468) and, most critically, the outcomes of the randomized Phase 2 HNSCC trial (NCT05909904) will be the key inflection points.

A crucial recommendation for the program's success is an intensive focus on translational science. The analysis of biomarker data from the clinical trials is not merely an academic exercise but a strategic imperative. Identifying a robust predictive biomarker—whether it be baseline TIM-3 expression levels on specific immune cell subsets, a composite gene expression signature, or another molecular correlate—will be essential for designing a successful, biomarker-stratified Phase 3 trial. Such a strategy would maximize the probability of demonstrating a significant clinical benefit and is a key lesson learned from the broader history of targeted oncology drug development.

In conclusion, Surzebiclimab stands at a critical juncture. It is a well-designed molecule with a strong scientific rationale, being advanced by a capable and experienced developer. It represents one of the last major efforts to clinically validate the TIM-3 pathway in solid tumors. If its upcoming trials are successful, it could usher in a new era of multi-checkpoint combination therapy and redefine the standard of care in select cancers. If it fails, it will serve as a powerful, cautionary tale about the immense challenges of translating our growing understanding of tumor immunology into effective medicines, pushing the field to continue its search for the next generation of transformative cancer therapies.

Works cited

1. Research Grade Surzebiclimab - Cell Sciences, accessed October 31, 2025, https://www.cellsciences.com/PDF/DHJ28403B.pdf
2. Surzebiclimab: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 31, 2025, https://go.drugbank.com/drugs/DB16669
3. Definition of surzebiclimab - NCI Drug Dictionary - National Cancer Institute, accessed October 31, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/surzebiclimab
4. Surzebiclimab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed October 31, 2025, https://synapse.patsnap.com/drug/0376352ed1434efd918590d2c86b4330
5. Surzebiclimab API Suppliers - Find All GMP Κατασκευαστές, accessed October 31, 2025, https://pharmaoffer.com/el/api-excipient-supplier/other-substances/surzebiclimab
6. United States Adopted Name (USAN) Drug Finder, accessed October 31, 2025, https://searchusan.ama-assn.org/finder/usan/search/KL-130/relevant/1/
7. Surzebiclimab API Price per kg: B2B transaction history, accessed October 31, 2025, https://pharmaoffer.com/api-excipient-supplier/transactions/surzebiclimab
8. Surzebiclimab (BGB-A425) | Anti-TIM-3 Antibody | MedChemExpress, accessed October 31, 2025, https://www.medchemexpress.com/surzebiclimab.html
9. Surzebiclimab (BGB-A425) - AbMole BioScience, accessed October 31, 2025, https://www.abmole.com/products/surzebiclimab.html
10. Surzebiclimab|Cas# - GlpBio, accessed October 31, 2025, https://www.glpbio.com/fr/surzebiclimab.html
11. Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in ..., accessed October 31, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT293421
12. SURZEBICLIMAB - precisionFDA, accessed October 31, 2025, https://precision.fda.gov/ginas/app/ui/substances/bd9d3b13-bf75-437b-a820-97db7722013b
13. Surzebiclimab by BeiGene for Advanced Malignancy: Likelihood of Approval, accessed October 31, 2025, https://www.pharmaceutical-technology.com/data-insights/surzebiclimab-beigene-advanced-malignancy-likelihood-of-approval/
14. surzebiclimab (BGB-A425) / BeOne Medicines - LARVOL DELTA, accessed October 31, 2025, https://delta.larvol.com/Products/?ProductId=0293efbe-fd27-4b17-8108-8b60bd063758
15. Surzebiclimab Biosimilar – Anti-HAVCR2 mAb – Research Grade - ProteoGenix, accessed October 31, 2025, https://us.proteogenix.science/product/surzebiclimab-biosimilar-anti-havcr2-mab-research-grade/
16. Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors - NCI - National Cancer Institute, accessed October 31, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2019-00104
17. NB-64-82310-5mg | Surzebiclimab Clinisciences, accessed October 31, 2025, https://www.clinisciences.com/en/other-products-186/surzebiclimab-24616647.html
18. Surzebiclimab - BeOne Medicines - AdisInsight - Springer, accessed October 31, 2025, https://adisinsight.springer.com/drugs/800054261
19. NCT03744468 | Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors | ClinicalTrials.gov, accessed October 31, 2025, https://www.clinicaltrials.gov/study/NCT03744468
20. Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and Surzebiclimab (anti-TIM-, accessed October 31, 2025, https://www.beonemedinfo.com/CongressDocuments/Zhu_Triple_Combination_Preclinical_AACR_Poster_2024.pdf
21. Abstract 4041: Translational assessment of triple combination with Tislelizumab (anti-PD-1), LBL-007 (anti-LAG-3) and < for Surzebiclimab (anti-TIM-3) highlights its strong anti-tumor activity and < for clinical potential in solid tumors such as HNSCC | Cancer Research - AACR Journals, accessed October 31, 2025, https://aacrjournals.org/cancerres/article/84/6_Supplement/4041/741068/Abstract-4041-Translational-assessment-of-triple
22. Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors | Clinical Research Trial Listing - CenterWatch, accessed October 31, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT03744468/study-of-bgb-a425-and-lbl-007-in-combination-with-tislelizumab-in-advanced-solid-tumors
23. Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11898530/
24. bgne-20231231 - SEC.gov, accessed October 31, 2025, https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/bgne-20231231.htm
25. Likelihood of Approval and Phase Transition Success Rate Model, accessed October 31, 2025, https://www.globaldata.com/store/report/surzebiclimab-in-advanced-malignancy-loa-innovation-and-trend-analysis/
26. NCT05909904 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | ClinicalTrials.gov, accessed October 31, 2025, https://www.clinicaltrials.gov/study/NCT05909904
27. Study Details | NCT03744468 | Study of BGB-A425 and LBL-007 in ..., accessed October 31, 2025, https://clinicaltrials.gov/study/NCT03744468
28. Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors - AdisInsight, accessed October 31, 2025, https://adisinsight.springer.com/trials/700299034
29. Study of Tislelizumab, Pamiparib, and Other Investigation... - Clinical Trial Discovery, accessed October 31, 2025, https://clinicaltrial.be/en/details/188244?per_page=20&recruiting=1&enrolling_by_invitation=1&active_not_recruiting=1¬_yet_recruiting=0&completed=0&only_recruiting=0&only_eligible=0
30. NCT04164199 | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies | ClinicalTrials.gov, accessed October 31, 2025, https://clinicaltrials.gov/study/NCT04164199
31. Fruquintinib Enrolling by Invitation Phase 3 Trials for Cancer / Advanced Malignant Neoplasm Treatment - DrugBank, accessed October 31, 2025, https://go.drugbank.com/drugs/DB11679/clinical_trials?conditions=DBCOND0033490%2CDBCOND0020966&phase=3&purpose=treatment&status=enrolling_by_invitation
32. Serplulimab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 31, 2025, https://go.drugbank.com/drugs/DB17451
33. Population Pharmacokinetics and Exposure–Response Analysis of Serplulimab in Small Cell Lung Cancer Patients - PubMed Central, accessed October 31, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12424064/
34. Population Pharmacokinetics and Exposure-Response Analysis of Serplulimab in Small Cell Lung Cancer Patients - PubMed, accessed October 31, 2025, https://pubmed.ncbi.nlm.nih.gov/40932107/
35. Cemiplimab Side Effects: Common, Severe, Long Term - Drugs.com, accessed October 31, 2025, https://www.drugs.com/sfx/cemiplimab-side-effects.html
36. Cemiplimab Disease Interactions - Drugs.com, accessed October 31, 2025, https://www.drugs.com/disease-interactions/cemiplimab.html?professional=1
37. RYBREVANT® (amivantamab-vmjw) Side Effects: 1st Treatment EGFR Exon 20, accessed October 31, 2025, https://www.rybrevant.com/papillon/why-rybrevant/side-effects/
38. Two more reasons for GSK to be wary of Tim-3 | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline, accessed October 31, 2025, https://www.oncologypipeline.com/apexonco/two-more-reasons-gsk-be-wary-tim-3
39. GSK's trio of cancer discontinuations | ApexOnco - Clinical Trials news and analysis, accessed October 31, 2025, https://www.oncologypipeline.com/apexonco/gsks-trio-cancer-discontinuations
40. Surzebiclimab | MedPath, accessed October 31, 2025, https://trial.medpath.com/drug/275352fbef964e5b/surzebiclimab
41. BeiGene (BGNE) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat, accessed October 31, 2025, https://www.marketbeat.com/stocks/NASDAQ/BGNE/fda-events/
42. NDA 213217/S-009 SUPPLEMENT APPROVAL BeiGene USA, Inc. Attention: Sarah Ansell, PhD Director, Regulatory Affairs 1840 Gateway Dr - accessdata.fda.gov, accessed October 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/213217Orig1s009ltr.pdf
43. NDA 213217/S-011 ACCELERATED APPROVAL BeiGene USA, Inc. Attention: Sarah Ansell Director, Regulatory Affairs 1840 Gateway Drive, - accessdata.fda.gov, accessed October 31, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/213217Orig1s011ltr.pdf
44. BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® - Business Wire, accessed October 31, 2025, https://www.businesswire.com/news/home/20230919543475/en/BeiGene-Announces-Positive-Regulatory-Updates-in-Europe-and-the-U.S.-After-Recently-Regaining-Global-Rights-for-TEVIMBRA
45. BeiGene AUS Pty Ltd | Therapeutic Goods Administration (TGA), accessed October 31, 2025, https://www.tga.gov.au/resources/sponsor/beigene-aus-pty-ltd
46. FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer, accessed October 31, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanidatamab-hrii-previously-treated-unresectable-or-metastatic-her2
47. The EU door to China-based approvals is open | ApexOnco - Oncology Pipeline, accessed October 31, 2025, https://www.oncologypipeline.com/apexonco/eu-door-china-based-approvals-open